Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fulvestrant in HR-positive/HER2-low Breast Carcinoma: NCT07287917 Clinical Landscape Report 2026
18 September 2026
NCT07287917 clinical landscape for HR-positive/HER2-low Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Methylprednisolone in Amyotrophic Lateral Sclerosis: NCT07287397 Clinical Landscape Report 2026
18 September 2026
NCT07287397 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride in Metastatic Soft Tissue Sarcoma: NCT07291297 Clinical Landscape Report 2026
18 September 2026
NCT07291297 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Triple Negative Breast Cancer: NCT07297667 Clinical Landscape Report 2026
18 September 2026
NCT07297667 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Xaluritamig in Refractory Ewing Sarcoma: NCT07297979 Clinical Landscape Report 2026
18 September 2026
NCT07297979 clinical landscape for Refractory Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Poly ICLC in Triple Negative Breast Cancer: NCT07300475 Clinical Landscape Report 2026
18 September 2026
NCT07300475 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Metastatic breast cancer: NCT07299409 Clinical Landscape Report 2026
18 September 2026
NCT07299409 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Valemetostat Tosilate in Ovarian Cancer: NCT07303387 Clinical Landscape Report 2026
18 September 2026
NCT07303387 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Hodgkin's Lymphoma: NCT07302347 Clinical Landscape Report 2026
18 September 2026
NCT07302347 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in High grade B-cell lymphoma: NCT07308132 Clinical Landscape Report 2026
18 September 2026
NCT07308132 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Perflubutane in Breast Cancer: NCT07310758 Clinical Landscape Report 2026
18 September 2026
NCT07310758 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LM-103 in Uveal Melanoma: NCT07310784 Clinical Landscape Report 2026
18 September 2026
NCT07310784 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.